GlassScriptPhysician profile
Katelyn M Spence
NPI 1740601665
$3,431.40
in general payments reported to CMS, 2019-2025
40 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $855 · 2022: $876 · 2023: $780 · 2024: $588 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,699.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $346.93 | 2021-2024 | Tecvayli, Talvey, Darzalex |
| Novartis Pharmaceuticals Corporation | $256.98 | 2023-2024 | |
| Celgene Corporation | $245.85 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Abbvie INC. | $215.69 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $214.37 | 2021-2023 | Imbruvica |
| Pfizer INC. | $178.88 | 2021-2025 | |
| Genzyme Corporation | $159.38 | 2021-2025 | |
| Incyte Corporation | $147.67 | 2021-2025 | Pemazyre, Monjuvi, Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $123.87 | 2021-2025 | |
| Lilly USA, LLC | $120.43 | 2021-2024 | Verzenio |
| Blueprint Medicines Corporation | $112.25 | 2022-2025 | Ayvakit |
| Ipsen Biopharmaceuticals, INC | $110.67 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $109.02 | 2021-2025 | Keytruda, Keytruda Qlex, Welireg |
| Eisai INC. | $91.66 | 2021-2024 | |
| Seagen INC. | $86.33 | 2022-2023 | Adcetris |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Spence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.